PXT3003, A FIXED COMBINATION OF BACLOFEN, NALTREXONE AND SORBITOL, FOR THE TREATMENT OF CHARCOT-MARIE-TOOTH DISEASE TYPE 1A (CMT1A): STATUS OF A MULTICENTE... S Attarian,T Sevilla,P Van Damme,... - 《Journal of the Peripheral Nervous System》...
An exploratory randomised double-blind and placebo-controlled phase 2 study of a combination of baclofen, naltrexone and sorbitol (PXT3003) in patients with Charcot-Marie-Tooth disease type 1A Shahram Attarian, Jean-Michel Vallat, Laurent Magy, Benoît Funalot, Pierre-Marie Gonnaud, Arnaud...